Abstract
Cardiovascular disease and its clinical sequelae remain the leading causes of morbidity and mortality in many regions of the world. Dyslipidemia is a critical risk factor to intercept in both the primary and secondary prevention of acute cardiovascular events. The prospective, placebo-controlled clinical trials conducted with statins over the course of the past 15 years have conclusively demonstrated that these drugs significantly reduce risk for fatal and nonfatal myocardial infarction, ischemic stroke, unstable angina, and frequency of myocardial ischemia, as well as cardiovascular and all-cause mortality. Of considerable interest is the fact that, even under the exquisitely controlled circumstances of a clinical trial, endpoint reductions in these trials typically occur in the range of 20% to 35%. Understandably, much attention is now being focused on deriving the pharmacologic means by which to further increase the magnitude of endpoint reduction. Epidemiologic investigation has demonstrated that the relationship between cholesterol and risk for atherosclerotic disease is a continuous one. Consequently, it is reasonable to assume that more aggressive reductions of low-density lipoprotein (LDL) cholesterol might result in even greater reductions of cardiovascular event rates and atheromatous plaque progression than heretofore observed. Two recent clinical trials, Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) and Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT), prospectively tested and confirmed the validity of more aggressive LDL cholesterol lowering in high-risk patients with established coronary artery disease.
Similar content being viewed by others
References and Recommended Reading
Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333: 1301–1307.
Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279: 1615–1622.
Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335: 1001–1009.
The LIPID Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339: 1349–1357.
Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1999, 344: 1383–1389.
Serruys PW, de Feyter P, Macaya C, et al., for the Lescol Intervention Prevention Study (LIPS) Investigators: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. A randomized controlled trial. JAMA 2002, 287: 3215–3222.
Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360: 7–22.
Sever PS, Dahlöf B, Poulter NR, et al., for the ASCOT Investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361: 1149–1158.
Verschuren WM, Jacobs DR, Bloemberg BP, et al.: Serum total cholesterol and long-term coronary heart disease mortality in different cultures: twenty-five-year follow-up of the Seven Countries Study. JAMA 1995, 274: 131–136.
Stamler J, Daviglus ML, Garside DB, et al.: Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000, 284: 311–318.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285: 2486–2497.
Pedersen TR, Olsson AG, Faergeman O, et al.: Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998, 97: 1453–1460.
Schwartz GG, Olsson AG, Ezekowitz MD, et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285: 1711–1718.
Nissen SE, Tuzcu EM, Schoenhagen P, et al., for the REVERSAL Investigators: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291: 1071–1080.
Cannon CP, Braunwald E, McCabe CH, et al., for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators: Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350: 1495–1504.
Ballantyne CM, Houri J, Notarbartolo A, et al., for the Ezetimibe Study Group: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003, 107: 2409–2415.
Ridker PM, Bassuk SS, Toth PP: C-Reactive protein and risk of cardiovascular disease: evidence and clinical application. Curr Atheroscler Rep 2003, 5: 341–349.
Illingworth DR: Management of hypercholesterolemia. Med Clin North Am 2000, 84: 23–42.
Sager PT, Melani L, Lipka L, et al., for the Ezetimibe Study Group: Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003, 92: 1414–1418.
Nissen SE, Tsunoda T, Tuzcu EM, et al.: Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. A randomized controlled trial. JAMA 2003, 290: 2292–2300.
LaRosa JC, for the TNT Steering Committee: Effect of lowering LDL-C beyond currently recommended targets: the Treating to New Targets study. Presented at the XIIIth International Symposium on Drugs Affecting Lipid Metabolism. Florence, Italy, May 1998.
MacMahon M, Kirkpatrick C, Cummings CE, et al.: A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr Metab Cardiovasc Dis 2000, 10: 195–203.
Pedersen TR, Faergeman O, Holme I, et al.: Effect of greater LDL-C reductions on prognosis: The Incremental Decrease in Endpoints through Aggressive Lipid Lowering (IDEAL) trial. Atherosclerosis 1999, 144: 38–43.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Toth, P.P. Low-density lipoprotein reduction in high-risk patients: How low do you go?. Curr Atheroscler Rep 6, 348–352 (2004). https://doi.org/10.1007/s11883-004-0045-2
Issue Date:
DOI: https://doi.org/10.1007/s11883-004-0045-2